In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Harrow Health (HROW – Research Report), with a price target of $57.00.
Yi Chen has given his Buy rating due to a combination of factors that highlight Harrow Health’s strong financial performance and promising growth prospects. The company reported significant revenue growth of 53% year-over-year in 2024, with expectations of over 40% growth in 2025. This impressive performance is supported by the success of their products, IHEEZO and VEVYE, which have shown substantial increases in sales and prescriptions.
Moreover, the recent approval of TRIESENCE for transitional pass-through reimbursement by the Centers for Medicare & Medicaid Services (CMS) is expected to further enhance Harrow’s revenue potential. This approval allows TRIESENCE to be reimbursed separately in various healthcare settings, expanding its market reach. Overall, these developments suggest a robust growth trajectory for Harrow Health, justifying Yi Chen’s Buy rating and the $57 price target.